Tag: quarterly report

FREMONT, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today announced that it began production shipments of its IQ9S-3P™ Commercial Microinverter, the company's most powerful microinverter currently available across the United States. Built with advanced gallium nitride (GaN) technology, the IQ9S-3P Commercial Microinverter supports high-wattage solar panels up to 770 W and connects directly to three-phase 480Y/277 V (wye) grid configurations without requiring external transformers.

~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~

TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (“Cronos” or the “Company”) (NASDAQ: CRON) (TSX: CRON), an innovative global cannabis company,  announced today that it has filed with the Toronto Stock Exchange (the “TSX”), and the TSX has accepted, the Company’s notice of intention to make a normal course issuer bid (the “TSX NCIB”).

IRVINE, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (“CETY” or the “Company”) (Nasdaq: CETY), a clean energy technology company focused on sustainable energy and waste-to-value solutions, today announced the successful implementation of its advanced ORC component manufacturing initiative, which should substantially reduce production costs and improve supply chain efficiency for the Clean Cycle II (“CCII”) heat recovery systems.

PEKIN, Ill., June 15, 2026 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced that it has completed a sale transaction with a third-party corporate buyer for all of Alto Ingredients’ 2025 Section 45Z Clean Fuel Production Tax Credits generated from its low-carbon ethanol production.

FREMONT, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced the appointment of Shanker Trivedi to its board of directors, effective immediately.

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial